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The  aims  of  this  study  was  to evaluate  the  effects  of  oil-resin  of  Copaiba  (Copaifera  duckei  Dwyer),  aired
in vaginal  cream  on  the  reproductive  performance  of  female  rats  (Rattus  norvegicus).  To determine  the
components  of the  C.  duckei  oleoresin,  gas  chromatography  coupled  with  mass  spectrometry  (CG–MS)
was  used,  and  considering  the  trans-caryophyllene  sesquiterpene  as  a phytochemical  marker  in  the  ole-
oresin.  Due  to the  extensive  use  of  copaiba  oleoresin  in the  suppository  form  for  gynecological  infections,
an evaluation  was  carried  out  on  the  effects  of  copaiba  oleoresin  (Copaifera  duckei  Dwyer),  delivered  in
a vaginal  cream,  on  the  reproductive  performance  of female  Wistar  rats.  For  this  purpose,  three  groups
(n =  5–6/group)  of  female  rats  were  treated  as follows:  1 –  vaginal  cream  of  copaiba  oleoresin  (28.6 mg/kg),
2 – base vaginal  cream  and  3 – control  (physiological  saline  0.9%),  administered  intravaginally,  for  30
days  before  pregnancy,  and  from  day  zero  to day  20 during  pregnancy.  Laparotomy  was  performed  on
the 21st  day  of  pregnancy,  followed  by the  determination  of  reproductive  variables:  number  of  live  and
dead fetuses,  mass  of  the  fetuses  and  placentas,  number  of implantations  and  resorptions,  number  of
corpora  lutea,  pre-  and  post-implantation  loss,  and  analyses  of  the  fetuses  with  regard  to  external  and
internal  anomalies  and/or  malformations  (skeletal  and  visceral).  The  trans-caryophyllene  present  in the
sample is  suggested  as  a phytochemical  marker  and the  results  of  this  study  demonstrate  an absence  of
maternal  toxicity  and  foetotoxicity  embryofoetotoxicity  at the  dose  administered,  corresponding  to  ten
times the  recommended  dose  for use in  humans.  Accordingly,  no  signiﬁcant  statistical  difference  was
observed  between  the  treated  and  control  groups,  for the  variables  analyzed.
Thus,  it  is concluded  that  the  vaginal  cream  containing  2.5%  copaiba  oleoresin  is  safe  during  gestation,
in  female  rats  (Rattus  norvegicus)  of  the  Wistar  strain.ntroduction
Nowadays, traditional knowledge, particularly concerning the
roducts of Amazonian biodiversity, has become an important tool
n the development of new pharmaceutical products. Copaiba oil is
n important natural product used in traditional medicine.Pharmacological studies with the copaiba oleoresin show that
ts use is fully justiﬁed by the Indians. Tests in vivo and in vitro
ave shown that the oils of several species of Copaifera pos-
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sess anti-inﬂammatory, antiseptic, wound healing, antitumor and
antibacterial.
Various pharmacological applications of oleoresin of Copaifera
spp. have been described in literature, including antimicrobial and
antibacterial (Opdyke 1976; Miranda et al. 2000; Tincusi et al. 2002;
Santos et al. 2008), anti-helmintic (Pellegrino 1967; Gilbert et al.
1972), analgesic (Fernandes et al. 1992; Carvalho et al. 2005), anti-
inﬂammatory (Basile et al. 1988; Carvalho et al. 2005; Fernandes
et al. 1992; Veiga et al. 2001), healing (Brito et al. 1999), gastro-
protective (Paiva et al. 1998), antitumoral (Ohsaki et al. 1994; Lima
et al. 2003) and tripanomicide activities (Cascon et al. 1998), cer-
vicitis and leukorrhea (Le Cointe 1934).
Open access under the Elsevier OA license.It is commonly indicated as an anti-inﬂammatory, antiseptic
and healing product, mainly of the upper air and urinary tracts (Le
Cointe 1934; Basile et al. 1988; Carvalho and Cascon 2003; Carvalho
et al. 2005).
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Copaiba oleoresin is one of the most commonly used natural
roducts among the population of the Brazilian Amazon region,
here it has considerable economic and social signiﬁcance, as it is
 native product, and several communities depend on its extraction
or their livelihoods (Santos et al. 2001). Despite the existence of
arious vaginal creams on the market, the copaiba suppository has
lways been used by the population. Its application in gynecology is
ot recent, and copaiba suppositories have been sold in pharmacies
nd natural product stores throughout Brazil for many years.
The anti-inﬂammatory and antimicrobial activities are the most
ommonly investigated. Studies on rats using inﬂammatory pro-
ess models, such as carrageenan-induced edema, induction of
ranulomatous tissue and bradykinin, indicate that copaiba ole-
resin presents anti-inﬂammatory activity and low toxicity (Basile
t al. 1988). Lima et al. (2003) demonstrate that the oil of C.
ultijuga presents tumoricide activity in melanoma cells, both
n vivo and in vitro. The analgesic and anti-inﬂammatory activity
f C. duckei showed signiﬁcant results, when used via the topical
oute in the carrageenan-induced paw edema, granuloma, and cro-
on oil-induced dermatitis tests (Carvalho et al. 2005). In another
xperimental model involving acetic acid-induced colitis in rats, it
as observed that kaurenoic acid, applied together with the acetic
cid, decreased the inﬂammatory cell inﬁltrate and edema of the
ntestinal mucosa, suggesting its anti-inﬂammatory effect (Paiva
t al. 2003).
Santos et al. (2008) tested the antimicrobial activity of eight
pecies of the genus copaifera. The species C. Martii,  C. ofﬁci-
alis and C. reticulata exhibited good antibacterial activity against
ram-positive bacteria, including MRSA (Methicillin-Resistant
taphylococcus aureus)  strains. By contrast, all the oils tested were
nactive against gram-negative bacteria. Antifungal activity in the
pecies C. paupera and C. lucens, C. cearensis, C. langsdorfﬁ and C.
ultijuga proved to be moderate.
The copaíba oleoresin (Copaifera duckei)  showed antimicrobial
ctivity against strains of microorganisms studied (Candida albi-
ans, Cryptococcus neoformans, Saccharomyces cerevisiae, Bacillus
ereus, Enterococcus faecalis, Bacillus subtilis,  Streptococcus pyogenes,
treptococcus salivarius and Micrococcus luteus).  The formation of
nhibition halos was observed in all of the dosages of oleoresin.
he serial dilution test in broth showed correlation with the diffu-
ion in agar test. It was concluded that the oleoresin of C. duckei
wyer, in the conditions of this assay, presented bacteriostatic
nd bactericidal selective activity against gram-positive and fungi
icroorganisms in different concentrations, but it was  ineffective
gainst gram-negatives (Cabral 2008).
The pregnancy affects the vaginal environment by modifying
he immune and hormone balance, disappearance of vaginal dis-
harge, abnormal vaginal discharge and increased pH (Ghione and
e Palo 1996). These changes may  lead pregnant women to a pic-
ure of vulvovaginitis. The vulvovaginitis is bacterial polymicrobial
nfection that causes vaginal discharge without clinical signs of
nﬂammation. It occurs in 10% to 26% in pregnancy (Biswass 1993).
ts importance arises in pregnancy may  lead to premature labor
nd premature rupture of membranes (Sullivan and Smith 1993).
he term bacterial vaginosis is attributed to a syndrome in which
here is reduced amount of Lactobacillus sp. concomitant increase
n anaerobic organisms, like Gardnerella vaginalis, Mobiluncus and
acteroides, among others (Linhares et al. 1994).
Although the occurrence and diagnosis of vulvovaginitis in preg-
ant women are similar to nonpregnant women, the management
f various infections vulvar and vaginal during pregnancy is often
 dilemma. First, because some medications may  be teratogenic
o the fetus, and second, some infections can affect the neonate
irectly or trigger preterm labor, and ﬁnally, the qualitative and
uantitative changes in the microﬂora during pregnancy, some
nfections may  be more resistant to therapy (Sullivan and Smithe 18 (2011) 1013– 1023
1993). Given this, it becomes necessary to introduce new vaginal
creams in the pharmaceutical market that are safe and effective.
In this context it is important to emphasize the importance of
herbal preparations, because although the pharmaceutical industry
employ the most different techniques, such as molecular biology,
combinatorial chemistry and computational chemistry, natural
products are synthesized by a unique process of combinatorial
chemistry, the biological evolution and natural selection, which
provides a structural diversity of different molecules to biological
targets (Mcchesney et al. 2007).
Popular and even traditional use, are not sufﬁcient to ethically
validate natural products as effective and safe. The recommen-
dation or ofﬁcial authorization of their medicinal use should be
backed by supporting experimental evidence, and the safety of their
use should also be proven, including during the gestational period
(Simões 2000).
It was believed for some time that the uterus was  imperme-
able to external agents, and that the placenta constituted a true
barrier between the maternal and fetal organisms. The “placen-
tal barrier” concept was  disproven, at the beginning of the 1960s,
by the “Thalidomide Tragedy”, when signiﬁcant fetal defects were
caused with the ingestion of a single dose of the drug during ges-
tation (Smithells and Newman 1992).
The appraisal of reproductive performance consists of the
administration of the substance to be evaluated, in pregnant
females, from implantation to the end of gestation, which corre-
sponds to one day before the birth. Consequently, knowledge of
the stages of embryonic development is essential, as some stages of
development are more vulnerable than others (Rogers and Kavlock
2001).
The use of any drug during gestation, even natural products,
should always take in to consideration the risk-beneﬁt ratio. Repro-
ductive toxicology studies of natural products are still in the early
stages in Brazil, but they are necessary to enable medical profes-
sionals to prescribe the use of these natural products (Calixto 2005).
Lyra et al. (2005) evaluate the toxic effect of oil of neem seed
(Azadiracha indica A. JUSS), used in popular medicine as a repellent,
in pregnant rats. This study did not demonstrate maternal toxic-
ity and anti-implantation effect; however, there was reduction of
fetal body mass, which might indicate possible embryofoetotoxic-
ity. Based on the reports presented, this study seeks to evaluate the
reproductive performance, at pre-clinical level, of animals treated
with vaginal cream containing copaiba oleoresin.
Material and methods
Obtaining the copaiba oleoresin
The copaiba oil used in the study was obtained from the com-
pany Beraca Ltda, located in Ananindeua, in the state of Pará, Brazil.
According to the company’s report, the oil was obtained from the
species Copaifera duckei Dwyer.
Analysis of the copaiba oleoresin by gas chromatography
To determine the components of the C. duckei oleoresin, gas
chromatography coupled with mass spectrometry (CG–MS) was
used, following the method described by Adams (1995) and con-
sidering the trans-caryophyllene sesquiterpene as a phytochemical
marker in the oleoresin.
The Gas Chromatograph Agilent® 6850 was  used, coupled with
a 5973 (CG-EM) Mass Spectrometer, and Helium carrier gas, with
ﬂow of 1.5 ml/min, injector temperature of 270 ◦C, oven at 120 ◦C,
and detector at 300 ◦C. Capillary column DB −1.25 m − 0.32 mm,
0.25 m.  Injection volume of 1.0 l, split mode 20:1. Heating ramp:
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20 ◦C for 2 min, heating of 3 ◦C per min  up to 160 ◦C, and 8 ◦C per
in  up to 290 ◦C, maintained for 5 min. The sample was read in
can mode, with 40–600 AMU.
The sample was prepared according to the steriﬁcation method
escribed by the IUPAC (1987),  with adaptations described in
ethod 2 of the Manual de Métodos Analíticos (manual of ana-
ytical methods) of the Instituto Adolfo Lutz (2005).
The “external standard” technique was adopted to quantity
he copaiba oleoresin, using the trans-caryophyllene standard
Sigma–Aldrich Co.) as a marker. The quantiﬁcation was  performed
y the external standardization method, which consisted of con-
tructing a calibration curve with the standard of the compound
resent in the sample, thereby determining the concentration of
he given compound.
btaining the copaiba vaginal cream
The copaiba vaginal cream and the base cream were obtained
rom the Laboratório Farmacêutico Almeida Prado Ltda, in the city
nd state of São Paulo, Brazil, at a concentration of 2.5%, supplied
n polyethylene bottles.
eproductive toxicology study
nimals
Before the start of the activities, this project was submitted for
pproval by the Research Ethics Committee of the Federal Univer-
ity of Amapá, under registration number 003A/2007.
Male and female and albino rats (Rattus norvegicus)  of the Wistar
train were used, weighing around 250 g, supplied by the Mul-
idisciplinary Center for Biological Investigation in the Area of
cience in Laboratory Animals (CEMIB) of the University of Camp-
nas/Unicamp, São Paulo.
The female rats were acclimatized in the Drug Research Labora-
ory of the Federal University of Amapá, for seven days. They were
ept in polyethylene boxes with maximum capacity for ﬁve animals
ach, under a constant temperature of 23 ◦C ± 2 ◦C and light/dark
ycle of 12 h. After the acclimatization period, the female rats were
andomly drawn, to form the three groups: UG, TBVC and TCVC.
xperimental groups
The females were randomly distributed in three experimental
roups: the Control or Untreated Group (UG): Untreated pregnant
ats, which received 0.5 ml  of physiological saline intravaginally for
0 days and throughout their pregnancy (n = 5); the Group Treated
ith Base Vaginal Cream (TBVC): Pregnant rats, which received
nly the base vaginal cream, intravaginally, in the same quantity
s that used in the group treated with copaiba vaginal cream, for
0 days and throughout pregnancy (n = 5); and the Group Treated
ith Copaiba Vaginal Cream (TCVC): Pregnant rats, which received
 dose of 28.6 mg/kg of copaiba vaginal cream, intravaginally, cor-
esponding to 10 times the dose that would be used in humans, for
0 days and throughout the pregnancy (n = 6).
xperimental sequence
ating period
After the acclimatization period, and on reaching sexual matu-
ity, the female rats were treated for 30 days, according to their
xperimental group. The mating phase started after this period,
asting for approximately 20 days. For mating purposes, the phase
f the estral cycle of each female rat was observed in the morning by
eans of a vaginal smear, classifying the phase as proestrus (12 h),
strus (14 h, ovulation occurs spontaneously half way through the
ark cycle during this phase.), metaestrous (21 h), or diestrus (57 h).e 18 (2011) 1013– 1023 1015
After detecting the proestrus phase, the female rats were dis-
tributed in pairs, in polyethylene cages, with appropriate bedding,
in the presence of a male rat at the end of the afternoon. The follow-
ing morning, the males were removed and the vaginal smears were
collected by introducing a 10 l pipette and aspirating with 0.9%
physiological saline solution (Marcondes et al. 2008). The presence
of spermatozoids was  considered indicative of pregnancy, associ-
ated with the diagnosis of the estrous phase of the estral cycle.
This phase is characterized as the maximum estrogenic phase. The
day on which pregnancy was conﬁrmed was considered day zero
(Calderon 1988).
Pregnancy period
The three different groups of pregnant rats, Control, TCVC and
TBVC, received, intravaginally, 0.5 ml  physiologic saline, 28.6 mg/kg
of copaiba vaginal cream, and the base vaginal cream, respectively,
until the 20th day. The treatment was  always administered in the
morning, adjusting the doses every ﬁve days, according to the
weight of the rats.
During pregnancy, the females were kept in individual cages for
21 days, weighed on days 0, 5, 14 and 21, and observed in relation
to behavior and water and food ingestion.
Cesarian procedure
On the 21st day of pregnancy, the rats were anesthetized with
50 mg/kg of sodium thiopental (Thiopentax®, Cristalia Ltda.) to per-
form the laparotomy, exposing the uterine horns to observe the
resorption nodules, and removing of the ovaries to count the cor-
pora lutea. The fetuses and placentas were immediately removed.
After this procedure, the mothers were submitted to euthanasia by
volemia depletion. The newborns were immediately analyzed and
then weighed and measured (Calderon 1988).
Evaluation methods
Maternal weight
A set of Gehaka BG4000 scales was  used for the daily weight
evaluation, and the weight gain was calculated by the differences
in body weight observed on days zero, 5, 14 and 21 of pregnancy.
Maternal reproductive performance
The implantation sites, resorption nodules and numbers of live
and dead fetuses were observed and counted. The ovaries were
also observed, in order to count the corpora lutea, with the aid of a
Nikow® magnifying glass, model SMZ  645 (C-W 10x A/22).
The embryo loss rate in the period preceding implantation was
denominated pre-implantation loss percentage, and was calculated
by the following formula:
Nr. of corpora lutea − Nr. of implantation
Nr. of corpora lutea
× 100
The death of the embryos after their implantation process
(percentage of post-implementation loss) was calculated by the
following formula:
Nr. of implantations − Nr. of live fetuses
Nr. of implantation
× 100
Test to conﬁrmation the implantation and of resorption sites
In cases of absence of fetal development or visible implanta-tion sites, the uterus was  placed in a 0.2% NaOH solution to reveal
whether there was any implantation site in that uterus. If the 0.2%
NaOH solution revealed the presence of an invisible implantation
site, it was  then considered NaOH positive (+).
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pectrometer.
eight and classifying the newborns
After the laparotomy, the newborns were weighed using a set
f Marte scales. The newborns were classiﬁed as AAP (Adequate
or Age of Pregnancy), SAP (Small for Age of Pregnancy) and LAP
Large for Age of Pregnancy), according to their body weights, in
ccordance with the parameters established by Calderon (1988):
AP: body weight between the mean weight of the control group,
lus or minus the standard deviation; SAP: body weight below the
ean weight of the control group, minus the standard deviation
nd LAP: body weight above the mean weight of the control group,
lus the standard deviation.
eight of the placentas and placental index
The placentas, without the membrane and umbilical cord, were
eighed on a set of Marte scales. The placental index (PI) was  deter-
ined by the ratio between the placental weight (PW) and the fetal
eight (FW) (Calderon 1988).
I = PW
FW
nalysis of external malformations
After the weighing, the newborns were examined externally,
eticulously analyzing the eyes, mouth, ear implantation, cranial
hape, fore and rear limbs, anal perforation and tail (Wilson 1965).
nalysis of visceral anomalies and malformations
Immediately after the external examination, half of the new-
orns from each litter were placed in Bouin solution for four days,
or ﬁxing of the visceral structures and decalciﬁcation of the bones.
hey were then placed for two days in 80% hydroalcohol solution,
hich was later replaced by 90% hydroalcohol solution, up until the
ay of analysis. The serial sectioning method was used to observe
isceral anomalies and/or malformations, according to the descrip-
ions proposed by Wilson (1965).  The analyses were carried out
ith the help of a Nikon® microscope, model SMZ  645 (C-W 10x
/22).nalysis of skeletal anomalies and/or malformations and count of
ssiﬁcation points
The method described by Staples and Schnell (1964) was used
o analyze the skeletal anomalies and/or malformations. Half of thetained in a 6850 (Agilent®) Gas Chromatograph coupled with 5973 (CG-EM) Mass
newborns from each litter were placed in 70% hydroalcohol solu-
tion for 12 h. The newborns were then placed in acetone P.A for
24 h, eviscerated, diaphanized and stained with alizarin red dye.
The analyses were conducted according to the method described by
Aliverti et al. (1979).  Ossiﬁcation points were observed and counted
in the litter processed for the analysis of skeletal malformations.
The ossiﬁcation points were evaluated in the following places: ster-
num, anterior and posterior phalanges, metacarpals, metatarsuses
and cervical and caudal vertebrae.
Statistical analysis
Analysis of variance (ANOVA) was  used to compare the body
weight values, followed by Tukey’s Test. The Kruskal–Wallis non-
parametric test (Siegel 1970) was used to compare the mean values
of the parameters of reproductive performance, fetal and placental
weights, and placental index of the experimental groups. The Chi-
squared Test (Berquó and Souza 1981) was  used to compare the
percentages of SAP, AAP and LAP. The Goodman test (Goodman
1964) was used to evaluate the incidence of malformations or of
fetal anomalies in the untreated and treated groups. Results with
p < 0.05 were considered statistically signiﬁcant.
Results
Analysis of copaiba oleoresin by gas chromatography
Fig. 1 and Chart 1 represent the chromatogram of the sample
steriﬁed by the IUPAC method, and unsteriﬁed, presenting the most
abundant and well-resolved peak, caryophyllene, and retention
times of the components. The copaiba oleoresin samples exhib-
ited a caryophyllene content of around 500 ng/ml (0.5%), which
represents an adequate range for quantiﬁcation by the proposed
method.
Maternal weight
During the 30-day treatment period and gestation period (from
day zero to day 21) no visible clinical signs of maternal toxicity,
such as weight loss or reduced feed intake, were recorded.
The mean weight of the female rats of the Control group, TBVC
and TCVC presented very similar values, with no signiﬁcant sta-
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Oleoresin – IUPAC Oleoresin – Unsterified
RT COMPOUND RT COMPOUND
4,54 4 Cyclohexene 4,556 Cycl ohexene
4,75 4 Α-Cubebene 4,766 α.-Cubebene
5,21 8 α.-Copaene 5,231 α.-Copaene
5,42 2 Cyclohexane 5,434 Cycl ohexane/  β-el emene
5,65 1 3H-3a,7-Methanoazulene, 5,670 α-Gurjunene
5,84 2 trans-Caryoph yllene 5,861 trans-Caryoph yllene
5,98 8 Caryop hyll ene 6,007 Caryoph yll ene
6,18 5
1-ethenyl-1-methyl-2-
(1-methylethenyl)-4- (1-
methylethylidene) -
bicyclogermacrene
6,204 γ-Elemene
6,29 3 trans-α-Bergamotene 6,312 trans-.α.-Bergamotene
6,62 4 alpha.-Caryoph yllene 6,643 α.-Humule ne
6,77 7 1H-Cyclop rop [e]azulene 6,789 1H-Cyclop rop[e]azulene
7,07 6 Naphthalene 7,095 Naphthal ene
7,17 1 Germacrene D 7,197 Germacrene-D
7,28 6 α-Selinene 7,311
1H-Cyclop rop[e]azulene, 
decahydro- 1,1,7-
trimethyl-4-met hylene
7,52 1 4,7-Methanoazulene 7,540
4,5-dimet hyl-11-
methylenet ricycl o[7.2.1.0(4.9)]do
decane
7,84 6 β-Bisabolene 7,629 α-Muurolene
8,12 6 delta.-Cadinene 7,871 beta.-Bisabolene
8,63 5 cis-α-bisabolene 8,151 γ-Cadinene
8,92 1 Germacrene B 8,666 cis-α-bisabolene
9,36 6 Caryoph yllene oxide 8,953 Germacrene B
10,384 - 9,398 Caryoph yll ene oxide
21,225 Palmitic acid-methyl  Ester 10,422 Fonenol
28,687 Linolei c acid, methyl Ester
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Maternal reproductive performance
Of the ﬁve and six female rats mated from the Control and TCVC
groups, respectively, all had a full term pregnancy (100%). How-Chart 1. Composition of C. duckei oleoresin and the respec
istical difference observed among these groups from day zero to
ay 21 of pregnancy. Treatment with the copaiba oleoresin vaginal
ream did not affect maternal weight in any period of pregnancy
Table 1).
The development of maternal weight gain was  progressive dur-
ng the pregnancy period for all the groups studied. Some female
ats of the TBVC and TCVC groups attained a weight gain above
0 g at the end of pregnancy. In the Control group this increase was
maller, with values below 75 g (Fig. 2). No signiﬁcant difference
as observed among the three groups.
able 1
eights (g) of the female rats of the Control, Base Vaginal Cream and Copaiba Vagi-
al Cream groups, expressed in mean ± standard deviation, according to the day of
regnancy.
Control TBVC TCVC
Day zero 251.4 ± 23.3 252.8 ± 15.6 252.1 ± 19.8
Day 5 266.6 ± 20.6 270.6 ± 17.3 267.8 ± 16.1
Day 14 293.2 ± 20.2 296.8 ± 17.2 294.5 ± 19.4
Day 21 344.4 ± 22.0 363.4 ± 18.3 346.0 ± 37.2
 = 5–6/group. The values do not differ from one another at a level of 5%. ANOVA,
ollowed by Tukey’s test.tention times (RT) of the steriﬁed and unsteriﬁed sample.Fig. 2. Evolution of weight gain of the female rats, expressed in grams (g), of the
Control, TBVC and TCVC Groups, according to the day of pregnancy. The columns
represent the mean values and standard deviation for the variable weight of
n  = 5–6/group.
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Table 2
Number of female rats mated, full term pregnancy and loss rates (%) before and after
implantation of the blastocyst in the pregnant rats of the Control, TBVC and TCVC
groups.
Control TBVC TCVC
Mated female rats 5 6 6
Full  term pregnancy 5 5 6
Rate of full term pregnancy (%) 100 83.33 100
Pre  loss (%) 30.76 6.66 45.53
Post loss (%) 22.22 0 3.33
n = 5–6/group. The values do not differ from one another at the level of 5%.
Kruskal–Wallis Test.
Table 3
Weight of the rat pups (fetal weight), expressed as mean and standard deviation, of
the female rats of the Control, TBVC and TCVC groups.
Control TBVC TCVC
Minimum 2.93 3.85 3.98
Maximum 6.24 5.42 7.25
Median 4.77 4.85 4.78
p25  4.63 4.60 4.54
p75  5.00 5.03 4.97
Arithmetic mean 4.82 4.81 4.82
Standard deviation 0.52 0.35 0.56
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Table 5
Placental index (PI), obtained by the ratio between each placental weight and respec-
tive fetal weight of the female rats of the Control, TBVC and TCVC groups.
Control TBVC TCVC
Minimum 0.06 0 0.05
Maximum 0.13 0.11 0.16
Median 0.08 0.08 0.08
p25 0.07 0.07 0.07
p75  0.09 0.08 0.08
Arithmetic mean 0.08 0.07 0.08
Standard deviation 0.01 0.01 0.02
n/groups: Control (n = 34); TBVC (n = 51) and TCVC (n = 43). The values do not differ
from one another at a level of 5%. Kruskal–Wallis Test./groups: Control (n = 34); TBVC (n = 51) and TCVC (n = 43). The values do not differ
rom one another at a level of 5%. Kruskal–Wallis Test.
ver, of the six female rats mated from the TBVC group, only ﬁve
eached the end of their pregnancy (83.33%). This difference was
ot signiﬁcant when compared with the Control and TCVC groups
Table 2).
The pre-implantation loss was greater in the TCVC group, and
he post-implantation loss was greater in the control group, how-
ver, there was no statistically signiﬁcant difference among the
hree groups analyzed (Table 2).
eight of the fetuses and placentas, and placental index
The presence of stillborns was not veriﬁed among the three
roups after the laparotomy. In the group treated with copaiba
leoresin vaginal cream (TCVC) the mean fetal weight was  4.82 g
nd the placental weight was around 0.5 g, determining a mean
lacental index of 0.08 g. No signiﬁcant difference was observed
mong these parameters in relation to treatment with the base
aginal cream (TBVC), which contained only the components of the
ormulation, or the control group (UG), which received only phys-
ological solution at 0.9%. These evaluation parameters are shown
n Tables 3–5.est to conﬁrmation the implantation and resorption sites
In immersing the uterus in the solution containing sodium
ydroxide at 0.2%, the invisible resorption nodules were revealed
able 4
eight of the placentas (placental weight) of the female rats from the Control, TBVC
nd  TCVC groups, expressed as mean and standard deviation.
Control TBVC TCVC
Minimum 0.31 0.28 0.28
Maximum 0.61 0.6 0.94
Median 0.40 0.38 0.38
p25  0.36 0.35 0.35
p75  0.43 0.42 0.43
Arithmetic mean 0.40 0.39 0.41
Standard deviation 0.07 0.06 0.12
/groups: Control (n = 34); TBVC (n = 51) and TCVC (n = 43). The values do not differ
rom one another at a level of 5%. Kruskal–Wallis Test.Fig. 3. The columns represent the means ± standard error of the mean resorption
variable for the female rats of the Control group, TBVC and TCVC of n = 5–6/group. It
was not signiﬁcant for p < 0.05.
and after the observation, were identiﬁed as positive, NaOH (+).
This revelation occurred in the uterus of three rats (3/6) treated
with the copaiba oleoresin vaginal cream (TCVC) and in the uterus
of all the rats (5/5) of the control group. Although the resorptions
were high in the control group (Fig. 3), there was  no signiﬁcant
difference among the three groups.
Weight and classiﬁcation of the newborns
The majority of newborn pups of female rats of the TCVC and
TBVC groups presented weights which were classiﬁed as Adequate
for the Age of Pregnancy (AAP), of 72.1% and 72.5%, respectively.
The percentage of newborns classiﬁed as Small for Age of Pregnancy
(SAP) was higher in the TCVC group; nevertheless, this difference
was not statistically signiﬁcant, at a level of 5%, when compared
with the other groups, Control and TBVC (Table 6).
The predominance of AAP newborns, with equal numbers for
LAP and SAP, was not related to the use of the copaiba oleoresin
vaginal cream, although it was observed that the percentage of
small pups (SAP) was  lower in the control group, no signiﬁcant
statistical difference was  observed (Fig. 4).
Table 6
Percentage (%) of newborns classiﬁed as small (SAP), adequate (AAP) and large (LAP)
for  Age of pregnancy, from female rats treated with Copaiba Vaginal Cream (TCVC),
Base Cream (TBVC) and Control.
Control TBVC TCVC
SAP 2.9% 9.8% 14.0%
AAP  82.4% 72.5% 72.1%
LAP  14.7% 17.6% 14.0%
The values do not differ from one another at the level of 5%. Chi-squared Test.
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Table 8
Frequencies of external, skeletal and visceral anomalies and malformations in litters
and  newborn pups from female rats of the Control, TBVC and TCVC groups.
Control TBVC TCVC
External malformations
Newborns affected 0/36 1/51 2/43
Litters affected 0/5 1/5 2/6
External anomalies
Newborns affected 0/36 0/51 1/43
Litters affected 0/5 0/5 1/6
Skeletal malformations
Newborns affected 2/18 4/26 7/23
Litters affected 1/5 3/5 3/6
Skeletal anomalies
Newborns affected 8/18 15/26 12/23
Litters affected 3/5 5/5 3/6
Visceral malformations
Newborns affected 8/18 5/25 7/21
Litters affected 4/4 3/5 5/5
Visceral anomalies
Newborns affected 1/18 4/25 4/21
(Tappin et al. 2004; Veiga and Pinto 2002). Although the study by
Lameira et al. (2009) showed a seasonal variation in the chemical
composition of the volatile fraction of this species, this compound isLAP) for age of pregnancy, from female rats treated with copaiba vaginal cream
TCVC), base cream (TBVC) and control.
ount of ossiﬁcation points
The total count for ossiﬁcation points was, on average, 42.3,
9.6 and 39.9, respectively, for the Control, TBVC and TCVC groups.
reatment with copaiba oleoresin vaginal cream did not evidence a
igniﬁcant difference in the total or differential count of these ossi-
cation points, when compared with the TBVC and Control groups
Table 7).
nalysis of external and internal anomalies and malformations
skeletal and visceral)
No external malformations or anomalies were diagnosed in the
ontrol group. In spite of the occurrence of anomalies and/or mal-
ormations detected in the TBVC and TCVC groups, this difference
as not considered signiﬁcant. In relation to skeletal and vis-
eral malformations and/or anomalies, all the groups were affected,
hough with no signiﬁcant statistical difference at a level of 5%.
either did the number of litters affected present any signiﬁcant
ifference among the groups. Accordingly, the topical treatment
ith copaiba oleoresin did not increase the frequency of skeletal
nd visceral malformations and anomalies (Table 8).
Differential analysis of malformations and anomalies did not
vidence a signiﬁcant difference from the effect of the treatment
ith copaiba oleoresin, delivered in vaginal cream. Of the skele-
al malformations detected, the most visible in the three groups
as phalangeal agenesis (Fig. 5) and of the anomalies, the most
ommon one was “butterﬂy” sternebrae (Fig. 6). Nevertheless, the
ifferences were not considered signiﬁcant among the three groups
Table 9).
able 7
ean and standard deviation of the ossiﬁcation points for newborn pups of female
ats of the Control, TBVC and TCVC groups.
Control TBVC TCVC
Anterior phalanges 6.0 ± 2.4 4.9 ± 2.2 3.0 ± 1.7
Metacarpals 7.8 ± 0.4 8.0 ± 0.0 7.8 ± 0.5
Posterior phalanges 6.6 ± 2.3 5.3 ± 3.2 5.7 ± 2.9
Metatarsusals 9.7 ± 0.6 10.0 ± 0.0 10.0 ± 0.0
Caudal vertebra 3.9 ± 1.0 3.8 ± 1.1 3.8 ± 1.4
Sternebrae 3.9 ± 1.0 3.8 ± 1.1 3.8 ± 1.4
Total ossiﬁcation 42.3 ± 9.8 39.6 ± 7.7 39.9 ± 5.5
/group: Control (n = 18), TBVC (n = 26) and TCVC (n = 23). The values do not differ
rom one another at a level of 5%. Kruskal–Wallis Test.Litters affected 1/4 3/5 3/5
The values do not differ from one another at a level of 5%. Goodman Test.
Observing the details of visceral anomalies and malformations,
it is noted that the percentage of cryptorchidism in the control
group was  higher (22.2%) than in the TCVC group (14.3%), though
this difference was not signiﬁcant among the three groups ana-
lyzed. The TBVC group exhibited a higher percentage of visceral
anomaly, located in the lateral ventricle (Fig. 7), though this differ-
ence was not signiﬁcant (Table 10).
Discussion
Several studies report the use of the GC-EM technique for qual-
itative and quantitative analysis of copaiba oleoresin (Veiga et al.
1997; Rigamonte-Azevedo et al. 2004; Tappin et al. 2004; Biavatti
et al. 2006). This chromatographic technique was effective in this
study as it enabled the separation of the sample components, per-
mitting the identiﬁcation of constituents present in the C. duckei
Dwyer oleoresin used in the production of copaiba oil vaginal cream
(Fig. 1). The phytochemical marker trans-caryophyllene is available
on the market, and is used as standard in various copaiba oleoresin
quantiﬁcation studies. It is pinpointed as the factor responsible
for several pharmacological actions described in copaiba oleoresinTable 9
Percentage (%) of external and skeletal malformations and anomalies of newborn
pups from female rats of the Control, TBVC and TCVC Groups.
Control TBVC TCVC
External malformations and/or anomalies (%)
Poorly positioned eyes 0 2.0 0
Malformed tail 0 0 2.3
Skeletal malformations (%)
Metacarpal 5.6 0 8.7
Metatarsus 11.1 0 0.0
Phalangeal agenesis 27.8 30.8 30.4
Rib  agenesis 0.0 3.8 0.0
Rib  hypoplasia 0.0 3.8 0.0
Skeletal anomalies (%)
Atrophied sternebrae 5.6 0 4.3
Rudimentary sternebrae 5.6 3.8 17.4
Irregularly shaped sternebrae 0.0 0.0 4.3
Butterﬂy-shaped sternebrae 22.2 11.5 8.7
Skull – reduced ossiﬁcation 0.0 3.8 4.3
The values do not differ from one another at the level of 5%. Goodman Test.
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Fig. 5. Newborn from the TBVC group with normal phalanges (A) and with phalangeal agenesis (B) (observe the tip of the arrow).
d with
p
a
s
b
C
i
t
a
c
h
i
t

F
vFig. 6. Newborn from the Control group with normal sternebrae (A) an
resent in all the species of copaifera, and was consequently chosen
s a quality marker of the product studied here.
A study on the chemical composition of the oleoresin of several
pecies of common occurrence in Brazilian Amazon was performed
y Cascon and Gilbert (2000),  with C. guianensis,  C. duckei and
. multijuga, and all these species shows that signiﬁcant chem-
cal variation. All the samples analyzed only have in common
he sesquiterpenes -caryophyllene and -bergamotene which
re not restricted to the Copaifera genus. Copalic acid previously
onsidered a characteristic diterpene of the Copaifera genus is,
owever, not a reliable marker because it occurs only in traces,
f at all in C. duckei of all the samples analyzed and C. mul-
ijuga oleoresin is characterized by the great predominance of
-caryophyllene.
ig. 7. Section of the head, evidencing two normal lateral ventricles, from a newborn p
entricle (B) (observe the tip of arrow). the butterﬂy-shaped 5th sternebra (B) (observe the tip of the arrow).
Similarly, Veiga et al. (2007) also studied the chemical and
anti-inﬂammatory activity investigations from the Copaiba oils
obtained from C. multijuga, C. cearensis and C. reticulate, conﬁrming
the ﬁndings of Cascon and Gilbert (2000),  since chromatographic
studies showed that the main compound among sesquiterpenes
-caryophyllene was (57.5, 19.7 and 40.9%, respectively), -
humulene Followed by, -copaene, -bergamotene, -cadinene,
with different amounts in each oleoresin. However, species
have proved that, although similar, these oleoresins possess var-
ied composition and anti-inﬂammatory activity. In this study
-caryophyllene was  considered as a pharmacological and phyto-
chemical marker.
Mendonc¸ a and Onofre (2008) showed that the Copaiba oil (C.
multijuga Hayne) was able to inhibit the growth of three bacteria,
up from the Control group (A), and one from the TBVC group, with closed lateral
C.S. Lima et al. / Phytomedicin
Table  10
Percentage of visceral malformations and anomalies in newborns from female rats of
the  Control, Base Vaginal Cream (TCVC) and Copaiba Vaginal Cream (TCVC) groups.
Control TBVC TCVC
Visceral malformations (%)
Cryptorchidism 22.2 4 14.3
Hypoplastic Kidney 5.6 0 0.0
Supranumerary kidney 5.6 0 0.0
Microphthalmia 5.6 4 0.0
Anaphthalmia 0.0 0 4.8
Alteration in the nasal septum 5.6 0 9.5
Lung inversion 0.0 8 0.0
Aortic defect 0.0 4 0.0
Dextrocardia 0.0 4 0.0
Alteration in the interventricular septum 0.0 0 4.8
Visceral anomalies (%)
Lateral ventricle 5.6 12 4.8
Retinal alteration 0.0 4 4.8
Poorly positioned eyes 0.0 4 9.5
Cerebral hemorrhage 5.6 0 0.0
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he values do not differ from one another at a level of 5%. Goodman Test.
resenting a minimum inhibitory concentration of 1.56, 3.12 and
2.5% for E. coli, S. aureus and P. aeruginosa,  respectively.
Maternal exposure to chemical agents during the gestation
eriod can result in alterations in the fetal development. These
lterations depend on factors inherent to the maternal organ-
sm, placental functionality, or a direct action on the embryo-fetal
rganism itself, which in turn, can lead to the death of the fetus,
alformations and/or anomalies, or impairment of the physical
nd/or behavioral development of the newborn pup (Calliari-
artin et al. 2002).
The use of medicinal plants during gestation, even those with
opical use, can result in different alterations in embryo-fetal
evelopment, due to their effect on embryonary implantation,
esulting in abortive (embryolethality) or embryofoetoxicity effects
Almeida and Lemonica 2000; Lyra et al. 2005). Maternal repro-
uctive performance was evaluated in this study through the
bservation of certain parameters, such as maternal weight, num-
er of live fetuses and percentage of pre- and post-implantation
oss.
Taking into consideration the greater likelihood of absorption of
he drug during the gestational period, particular attention should
e paid, when performing the toxicological assays, to the evident
linical signs of maternal toxicity that have resulted in death or a
eduction in body weight gain (Calliari-Martin 1998).
It is important to emphasize that weight evaluation of pregnant
ats is one of the most relevant parameters, because it indirectly
valuates the degree of maternal and fetal impairment. Thus, we
an say that loss of body mass is one of the main indicators of
aternal toxicity (Lyra et al. 2005), as insufﬁcient weight gain
ay  result in restriction of intrauterine growth (Schwarez et al.
996). In this study, there was no signiﬁcant difference in weight
etween the female rats of the three groups; control, treated with
ase vaginal cream, and treated with the vaginal cream contain-
ng copaiba oleoresin, both in the pre-implantation period and in
he total gestation period, which suggests the absence of maternal
oxicity (Fig. 2).
In the pre-implantation period, the embryo has undifferen-
iated cells in mitotic division. The reduction in the number of
ells in the embryo, during this phase, can induce a delay in
he formation of the blastocyst (Kola and Folb 1986) and conse-
uently, an increase in pre- and post-implantation losses (Lemônica
t al. 1996). According to Almeida and Lemonica (2000), the rate
f pre-implantation loss establishes a correlation between the
umber of ova released and those that, after being fecundated,
anage to be implanted in the uterus. Post-implantation loss,e 18 (2011) 1013– 1023 1021
on the other hand, refers to the ratio between the number of
blastocysts implanted and those that did not manage to develop.
The implanted blastocyst, which did not manage to develop, is
given the name “resorption” and indicates a fault in embryonary
development.
The results of this study indicate that the copaiba oleoresin
delivered in a vaginal cream at 2.5% does not interfere in the pre-
and post-implantation phases, in the animal species studied and
at the dose tested here, which corresponded to ten times the dose
recommended for use in humans (Fig. 3, Tables 2–5).
The signiﬁcant reduction in mass of the fetuses in the groups
treated may  indicate a possible fetotoxic effect (Lyra et al. 2005).
No statistically signiﬁcant difference among the three groups was
observed in this study, in relation to the mass of the rat pups.
Therefore, the copaiba oil delivered in the vaginal cream, in the
concentration employed, did not determine the appearance of feto-
toxicity, even though the number of pups classiﬁed as small for
gestational age (SAP) was  higher in this group (Fig. 4, Table 6).
In the organogenesis period, there is intense proliferation and
migration of cells, remodeling of the tissues, and formation of the
rudimentary organs (Brent 1993). This period is characterized as
the most susceptible to teratogenic agents, with a higher probabil-
ity of occurrence of fetal malformations. The type of malformation
will depend on the embryonary stage and on the afﬁnity of the agent
for a particular embryonary tissue (Chang et al. 2002). This study
did not evidence any relation between the frequency of external
and internal anomalies and malformations (skeletal and visceral
analyses) with the use of the vaginal cream containing copaiba ole-
oresin. The use of C. duckei Dwyer oleoresin delivered in a vaginal
cream at 2.5%, administered in pregnant rats of the Wistar strain
during the pre-implantation and organogenesis period, proved to
be safe in this species for this variable (Tables 7–9).
Nonetheless, despite the differences, these results on the toxic
effects of copaiba oleoresin, corroborated the study by Lourenc¸ o
et al. (2008a) in relation to animal species (mouse, Swiss) and
administration route (gavage). But it showed that mice from the
negative control group and groups treated with three different
doses of the copaiba oil did not produce any malformation. Accord-
ing to the results of Lourenc¸ o et al. (2008b), copaiba oil does not
present any toxic potential, and it appears to have a protective effect
against hydrocephalus and vertebral malformation.
Despite the clinical use of many medications, there is no sufﬁ-
ciently reliable information available on the teratogenic potential
of many of them, and some are even controversial. Rosa (1996)
analyzed seventy pregnant women  exposed to a single dose of
itraconazole, during the ﬁrst trimester, and did not ﬁnd any evi-
dence of teratogenic effects. In another study, a retrospective cohort
trial, with pregnant women exposed to itraconazole during the ﬁrst
trimester of pregnancy, the prevalence was 13% (Bar-Oz et al. 1999).
In the context of topical antimicrobial medications, it is nec-
essary to consider the potential risk and the beneﬁt, both for the
mother and for the fetus, if the infection is treated or not. In this
case, it is important to consider the treatment of these infections
in the genital tract during gestation.
Although the data demonstrated in the study by Kazy et al.
(2005) are not equivalent, several issues should be considered. A
key point is the differences in teratogenic manifestations in humans
(with limb abnormalities) and mice (defects of the skeletal extrem-
ities) (Tiboni et al. 2008). These phenotypic differences may reﬂect,
as a ﬁrst hypothesis, a difference in sensitivity among species to
teratogen. This is a well-known phenomenon in teratology.
For this reason, the fact that the vaginal cream of copaiba oleo-
resin does not affect reproductive performance and does not cause
teratogenic effects in Wistar rats does not rule out the need for
further studies using other doses and other animal species, to eval-
uate the safety of this product in relation to embryotoxicity and
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eratogenicity, even though copaiba oleoresin is traditionally used
y women in the vaginal cavity to treat gynecological infections.
onclusion
Based on the results obtained, the trans-caryophyllene present
n the sample is suggested as a phytochemical marker, and the
reatment with the vaginal cream containing copaiba oleoresin
id not affect maternal weight during any phase of the pregnancy.
onsequently, the dose used was not capable of causing maternal
oxicity. It did not affect loss of the blastocyst before or after implan-
ation, and is therefore not embryofoetotoxic. During pregnancy, it
id not prevent the female rats from having a full term pregnancy,
either did it affect the mean weight of the newborns or placentas,
r the placental index. Thus it did not interfere in reproductive per-
ormance during pregnancy at the dose tested, and did not affect
he appearance of external anomalies and/or malformations. The
se of the vaginal cream containing 2.5% copaiba oil proved to be
afe during the gestation of Wistar rats (Rattus norvegicus).
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